Patent ID: 7930104

Claim:
A method for determining a likelihood that a breast cancer patient will have a beneficial response to treatment with chemotherapy, comprising: measuring expression levels of RNA transcripts of at least two genes selected from BIRC5, MKi67, MYBL2, CCNB1, STK6, MMP11, SCUBE2, ERBB2, GRB7, ESR1, PGR, BCL2, CTSL2, GSTM1, CD68, and BAG1 in a biological sample obtained from a breast tumor of the patient; calculating a risk score (RS) based on said expression levels, wherein said expression levels comprise one or more of the following variables: (i) Recurrence Score; (ii) ESR1 Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; (v) MYBL2 expression level; and (vi) SCUBE2 expression level, wherein each group score, MYBL2 expression level, and SCUBE2 expression level is weighted by its respective contribution to chemotherapy benefit, wherein the Recurrence Score, the Proliferation Group Score, the Invasion Group Score, and the MYBL2 expression level are positively correlated with the likelihood that the patient will have a beneficial response to chemotherapy, and wherein the ESR1 Group Score and the SCUBE2 expression level is negatively associated with the likelihood that the patient will have a beneficial response to chemotherapy; and creating a report based on the RS, comprising an estimate of the likelihood that the patient will have a beneficial response to chemotherapy.